Peregrine Asset Advisers’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Peregrine Asset Advisers’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.76M	Buy	49,039 +46,020	+1,524%	+$6.22M	1.68%	15
2026 Q1	$386K	Sell	3,019 -58,205	-95%	-$7.27M	0.1%	137
2025 Q4	$7.47M	Buy	+61,224	New	+$7.02M	2.11%	9
2024 Q2	–	Sell	-2,392	Closed	-$227K	–	189
2024 Q1	$227K	Sell	2,392 -38	-2%	-$3.53K	0.09%	153
2023 Q4	$217K	Buy	+2,430	New	+$180K	0.11%	148
2022 Q2	–	Sell	-12,227	Closed	-$1.1M	–	128
2022 Q1	$1.1M	Buy	+12,227	New	+$1.13M	0.56%	46
2021 Q4	–	Sell	-4,784	Closed	-$601K	–	158
2021 Q3	$601K	Buy	+4,784	New	+$616K	0.31%	64

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Peregrine Asset Advisers's XBI Position: Q2 2026 in Review

Peregrine Asset Advisers increased its State Street SPDR S&P Biotech ETF (XBI) stake by 1,524% in Q2 2026, buying an estimated $6.22M and bringing the position to 49,039 shares worth $7.76M. The position accounts for 1.68% of the portfolio, ranked #15.

Peregrine Asset Advisers first reported a position in XBI in Q3 2021 and has held it in 7 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Peregrine Asset Advisers held 49,039 shares of State Street SPDR S&P Biotech ETF worth $7.76M as of Q2 2026.
Peregrine Asset Advisers bought 46,020 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $6.22M.
State Street SPDR S&P Biotech ETF made up 1.68% of Peregrine Asset Advisers's portfolio in Q2 2026, its #15 holding.
Peregrine Asset Advisers first reported a position in State Street SPDR S&P Biotech ETF in Q3 2021 and has held it in 7 quarters since.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Peregrine Asset Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.